IDbyDNA is a Salt Lake City-based biotechnology company with a focus on metagenomics technology. The company has developed technologies and a platform that profile micro-organisms and pathogens simultaneously in high volumes. The company has a solution for recognizing particles, pathogens, and other micro-organisms, and they called it Explify Respiratory. The solution applies DNA and RNA sequencing to detect and identify bacterial, viral, fungal, and parasitic pathogens by their unique genome sequences. The company uses this technology to identify common and rare pathogens, especially ones difficult to culture, new strains, and complex co-infections.
COVID-19
Since the outbreak of COVID-19, IDbyDNA has made available their Explify Respiratory test which can detect 2019-nCoV as well as over 900 other pathogens. It has also partnered with Illumina to co-market the technology as well as develop it further for more advanced COVID-19 surveillance methods. IDbyDNA is in contact with and cooperates with public health agencies to ensure a coordinated response to suspected or confirmed cases of COVID-19 in patients. The test is able to adapt to emerging and changing pathogens. Their technology and test is a validated Laboratory Developed Test.
Timeline
Funding rounds
People
Guochun Liao
Co-Founder, CEO
Mark Yandell
Co-Founder, CSO
Martin Reese
Co-Founder, Chairman
Robert Schlaberg
Co-Founder, CMO
Further reading
IDbyDNA to Advance Platform, Now Including Novel Coronavirus, Expand Commercial Operations
Alex Philippidis
Web
January 29, 2020
Illumina taps IDbyDNA for infectious disease sequencing co-marketing initiative
Conor Hale
Web
March 18, 2020
Novel Wuhan Coronavirus Detectable with IDbyDNA Explify Respiratory Test
Web
January 28, 2020
Documentaries, videos and podcasts
D1 16:15 T1-Charles Chiu, UCSF; Robert Schlaberg, IDbyDNA; Heike Sichtig FDA; and Mickey Kertesz, Karius
February 14, 2017
Companies
IDbyDNA
Guochun Liao
Sunnyvale, California, United States